What do systematic reviews say?

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 870 participants
  Low

Insulin glargine vs NPH insulin

Summary of findings: insulin glargine showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.83 [0.62, 1.12]
  6 studies · 1893 participants
  Moderate

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  4.97 [0.79, 31.38]
  9 studies · 3334 participants
  Moderate

Summary of findings: insulin detemir vs NPH insulin

Summary of findings: insulin detemir probably leads to lower severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.69 [0.52, 0.92]
  8 studies · 3219 participants
  Moderate

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 495 participants
  Low

Summary of findings: insulin detemir vs NPH insulin

Summary of findings: insulin detemir showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.67 [0.39, 1.17]
  7 studies · 2925 participants
  Moderate

Summary of findings: insulin detemir vs NPH insulin

Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.95 [0.75, 1.21]
  9 studies · 3332 participants
  Moderate

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 3122 participants
  Moderate

Insulin glargine vs NPH insulin

Summary of findings: insulin glargine showed no clear difference in severe hypoglycaemia (n/N) Definition: symptomatic hypoglycaemia… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.84 [0.67, 1.04]
  9 studies · 2350 participants
  Moderate

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 585 participants
  Low

Insulin glargine vs NPH insulin

Summary of findings: insulin glargine showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.08 [0.63, 1.84]
  8 studies · 2229 participants
  Moderate

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 2285 participants
  Moderate

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  0.14 [0, 6.98]
  8 studies · 2175 participants
  Moderate

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1013 participants
  Low